Cohance Lifesciences jumps after broker initiates coverage

Cohance Lifesciences rose 1.57% to Rs 898.60 after a foreign broker initiated coverage on the stock with a buy call and a price target of Rs 1,150.

The brokerage said Cohance is well-positioned to benefit from Antibody Drug Conjugate (ADC) industry tailwinds, supported by a strong pipeline and multiple growth levers.

It expects destocking pressures in specialty chemicals and Pharma CDMO to ease soon, with recovery likely from FY26. Backed by integrated ADC offerings, a robust pipeline, and cross-selling opportunities, Cohance is projected to deliver 20% sales CAGR and 26% EBITDA CAGR over FY25-28, making it the broker?s top ADC play in India.

Cohance Lifesciences, formerly Suven Pharmaceuticals, is an innovator-focused global CRDMO formed through the merger of Cohance Life Sciences into Suven Pharmaceuticals.

Its consolidated net profit (adjusted) stood at Rs 62.9 crore, down 24.8% year-on-year from Rs 83.5 crore in Q1 FY25. Revenue from operations rose 12.5% YoY to Rs 549.3 crore from Rs 488.1 crore, aided by growth across all business segments.

Powered by Capital Market - Live News